A Phase Ib/II, Multicentre, Double-blind, Randomised, Placebo-controlled Dose-escalation and Dose-finding study to Evaluate the Safety and Efficacy of IPN59011 in improving appearance of Moderate to Severe Upper Facial Lines
Latest Information Update: 16 Jul 2023
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Glabellar lines
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms LONG-SET
- Sponsors Ipsen
Most Recent Events
- 22 Dec 2022 Status changed from active, no longer recruiting to discontinued.
- 09 Dec 2022 This trial has been discontinued in Germany (End Date: 22 Nov 2022) according to European Clinical Trials Database record.
- 11 Apr 2022 Planned number of patients changed from 424 to 412.